3
Mar
2017

Grail’s $900M Haul, Kite’s CAR-T Stands Up 6 Months, & Icahn Returns

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Megarounds Return, AZ Buys a Radiopharma Player, & Lonza’s California Dream
Madrigal’s Historic First for MASH, IFM’s Hat Trick, & BIO on Election Defense
Startups Challenge Vertex, BMS, Takeda & the Weight Loss Drug Revival Continues
Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist